Two Years Later: EECP for Patients w/ RAP and Left Ventricular Dysfunction

Two Years Later EECP for Patients w- RAP and Left Ventricular Dysfunction
Written by: Jennifer

This post is an excerpt from an article originally published in 2006 by the American Journal of Cardiology. Click the link at the bottom to read the full article.

Two-year clinical outcomes after enhanced external counterpulsation (EECP) therapy in patients with refractory angina pectoris and left ventricular dysfunction

Enhanced external counterpulsation (EECP) is a noninvasive circulatory assist device that has recently emerged as a treatment option for refractory angina in left ventricular (LV) dysfunction. This 2-year cohort study describes the long-term follow-up of patients who had severe LV dysfunction that was treated with EECP for angina pectoris and reports clinical outcomes, event-free survival rates, and the incidence of repeat EECP. This study included 363 patients who had refractory angina and LV ejection fraction < or =35%. Most patients reported quality of life as poor. After completion of treatment, there was a significant decrease in severity of angina class (p < 0.001), and 72% improved from severe angina to no angina or mild angina. Fifty-two percent of patients discontinued nitroglycerin use. Quality of life improved substantially. At 2 years this decrease in angina was maintained in 55% of patients. The 2-year survival rate was 83%, and the major adverse cardiovascular event-free survival rate was 70%. Forty-three percent had no reported cardiac hospitalization; 81% had no reported congestive heart failure events. Repeat EECP was performed in 20% of these patients. The only significant independent predictor of repeat EECP in a proportional hazard model was failure to complete the first EECP treatment course (hazard ratio 2.9, 95% confidence interval 1.7 to 4.9). Improvements in angina symptoms and quality of life were maintained at 2 years. In conclusion, for patients who have high-risk LV dysfunction, EECP offers an effective, durable therapeutic approach for refractory angina. Decreased angina and improvement in quality of life were maintained at 2 years, with modest repeat EECP and low major cardiovascular event rates.

More EECP Resources

One Year Later: RAP Patients Treated with EECP

Find out how patients receiving EECP therapy for refractory angina pectoris are doing one year post treatment.

Read More

EECP: Two-Year Outcomes in Patients with Mild Refractory Angina

Learn how EECP treats patients with mild to severe angina.

Read More

5 Years Later: Long-term Prognosis of Angina Treated with EECP

Clinical Cardiology examines the long-term effects of EECP therapy.

Read More